Summary
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.
History
Simulations Plus was founded in 1995 by Walt Woltosz, Marv Heckerman, and Brian Redmon, to develop medical software and consulting services. Walt had previously founded a company called WordCafe that developed medical information software used by healthcare providers. Simulations Plus was an offshoot of this business, and specialized in the development of software solutions and solutions for pharmaceutical companies. Simulations Plus has since become a leader in the areas of drug discovery, development, and testing.
Mission
Simulations Plus’ mission is to provide technologically advanced solutions to enable pharmaceutical and biotechnology companies to speed up the process of drug discovery and development.
Vision
Simulations Plus strives to be the premier provider of computer-aided drug discovery and development simulation and modeling solutions.
Key Team
Mr. William Frederick (CFO & Sec.)
Dr. Brett A. Howell Ph.D. (Pres of DILIsym Services, Inc)
Ms. Jill Fiedler-Kelly M.S., MS (Pres of Cognigen Division)
Ms. Viera Lukacova Ph.D. (Chief Science Officer)
Dr. Bud Nelson J.D., Ph.D. (VP of Corp. Counsel & Personal Data Protection Officer)
Ms. Arlene Padron (Corp. Director of Marketing)
Ms. Lindsay Luke (Exec. Director of HR)
Recognition and Awards
Simulations Plus has been recognized for its achievements, having received three awards from Deloitte, two R&D 100 Awards for drug design software, one Stevie Award for strategic consulting, and several other industry accolades
References
United States 